The more strong impacts of dapagliflozin over empagliflozin for heart failure can be explained by SGLT2 and SGLT1 receptor selectivity ratio that is lower for dapagliflozin as compared to empagliflozin [19]. The gene discussed is SLC5A2; the disease is heart failure.